IBDEI1KO ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26671,1,3,0)
 ;;=3^Medication-Induced Acute Dystonia
 ;;^UTILITY(U,$J,358.3,26671,1,4,0)
 ;;=4^G24.02
 ;;^UTILITY(U,$J,358.3,26671,2)
 ;;=^5003785
 ;;^UTILITY(U,$J,358.3,26672,0)
 ;;=G24.01^^100^1276^16
 ;;^UTILITY(U,$J,358.3,26672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26672,1,3,0)
 ;;=3^Tardive Dyskinesia
 ;;^UTILITY(U,$J,358.3,26672,1,4,0)
 ;;=4^G24.01
 ;;^UTILITY(U,$J,358.3,26672,2)
 ;;=^5003784
 ;;^UTILITY(U,$J,358.3,26673,0)
 ;;=G24.09^^100^1276^17
 ;;^UTILITY(U,$J,358.3,26673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26673,1,3,0)
 ;;=3^Tardive Dystonia
 ;;^UTILITY(U,$J,358.3,26673,1,4,0)
 ;;=4^G24.09
 ;;^UTILITY(U,$J,358.3,26673,2)
 ;;=^5003786
 ;;^UTILITY(U,$J,358.3,26674,0)
 ;;=G25.1^^100^1276^12
 ;;^UTILITY(U,$J,358.3,26674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26674,1,3,0)
 ;;=3^Medication-Induced Postural Tremor
 ;;^UTILITY(U,$J,358.3,26674,1,4,0)
 ;;=4^G25.1
 ;;^UTILITY(U,$J,358.3,26674,2)
 ;;=^5003792
 ;;^UTILITY(U,$J,358.3,26675,0)
 ;;=G25.71^^100^1276^15
 ;;^UTILITY(U,$J,358.3,26675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26675,1,3,0)
 ;;=3^Tardive Akathisia/Medication-Induced Acute Akatisia
 ;;^UTILITY(U,$J,358.3,26675,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,26675,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,26676,0)
 ;;=G25.79^^100^1276^10
 ;;^UTILITY(U,$J,358.3,26676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26676,1,3,0)
 ;;=3^Medication-Induced Movement Disorder NEC
 ;;^UTILITY(U,$J,358.3,26676,1,4,0)
 ;;=4^G25.79
 ;;^UTILITY(U,$J,358.3,26676,2)
 ;;=^5003800
 ;;^UTILITY(U,$J,358.3,26677,0)
 ;;=T43.205A^^100^1276^4
 ;;^UTILITY(U,$J,358.3,26677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26677,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
 ;;^UTILITY(U,$J,358.3,26677,1,4,0)
 ;;=4^T43.205A
 ;;^UTILITY(U,$J,358.3,26677,2)
 ;;=^5050540
 ;;^UTILITY(U,$J,358.3,26678,0)
 ;;=T43.205D^^100^1276^5
 ;;^UTILITY(U,$J,358.3,26678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26678,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,26678,1,4,0)
 ;;=4^T43.205D
 ;;^UTILITY(U,$J,358.3,26678,2)
 ;;=^5050541
 ;;^UTILITY(U,$J,358.3,26679,0)
 ;;=T43.205S^^100^1276^6
 ;;^UTILITY(U,$J,358.3,26679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26679,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
 ;;^UTILITY(U,$J,358.3,26679,1,4,0)
 ;;=4^T43.205S
 ;;^UTILITY(U,$J,358.3,26679,2)
 ;;=^5050542
 ;;^UTILITY(U,$J,358.3,26680,0)
 ;;=G25.71^^100^1276^7
 ;;^UTILITY(U,$J,358.3,26680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26680,1,3,0)
 ;;=3^Medication-Induced Acute Akathisia
 ;;^UTILITY(U,$J,358.3,26680,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,26680,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,26681,0)
 ;;=G24.02^^100^1276^9
 ;;^UTILITY(U,$J,358.3,26681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26681,1,3,0)
 ;;=3^Medication-Induced Acute Dystonia
 ;;^UTILITY(U,$J,358.3,26681,1,4,0)
 ;;=4^G24.02
 ;;^UTILITY(U,$J,358.3,26681,2)
 ;;=^5003785
 ;;^UTILITY(U,$J,358.3,26682,0)
 ;;=G21.0^^100^1276^13
 ;;^UTILITY(U,$J,358.3,26682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26682,1,3,0)
 ;;=3^Neuroleptic Malignant Syndrome
 ;;^UTILITY(U,$J,358.3,26682,1,4,0)
 ;;=4^G21.0
 ;;^UTILITY(U,$J,358.3,26682,2)
 ;;=^5003771
 ;;^UTILITY(U,$J,358.3,26683,0)
 ;;=T50.905A^^100^1276^1
 ;;^UTILITY(U,$J,358.3,26683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26683,1,3,0)
 ;;=3^Adverse Effect of Unspec Medication,Init Encntr
 ;;^UTILITY(U,$J,358.3,26683,1,4,0)
 ;;=4^T50.905A
 ;;^UTILITY(U,$J,358.3,26683,2)
 ;;=^5052160
